RxDoctor Payments Data

Parthenia Oliver, NP

Family · Tuscaloosa, ALNPI 1497868160

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 48 payments — averaging $27.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$336
  • Lilly USA, LLC$198
  • Gilead$175
  • Johnson & Johnson$171
  • Janssen Products, LP$130
  • AbbVie$125
  • plus $202 from 5 others

What the payments were for

  • Food & beverage$1,17988%
  • Education$15812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$336
Lilly USA, LLC3$198
Gilead9$175
Johnson & Johnson(2 entities)11$171
Janssen Products, LP2$130
AbbVie1$125
Viiv Healthcare Company2$67
Merck2$51
GSK3$47
Abbott1$23
Dexcom, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,338 in reported general payments places this provider in the 70th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$1,119
Medicare patients
21
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala19$77,107
OzempicSemaglutide62$70,789
MounjaroTirzepatide13$29,724
JardianceEmpagliflozin46$29,589
FarxigaDapagliflozin Propanediol21$11,857
MyrbetriqMirabegron17$8,343
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$5,713
Novolog FlexpenInsulin Aspart14$2,936
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid14$1,348
Albuterol Sulfate HfaAlbuterol Sulfate35$918
Potassium Chloride42$881
Buspirone Hcl16$822
Ulticare Pen NeedlePen Needle, Diabetic14$742
Omeprazole54$677
Losartan Potassium55$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$175$77,10719 claims
Novo NordiskOzempic$336$70,78962 claims
Lilly USA, LLCMounjaro$198$29,72413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,415 family providers in Alabama.

Other family in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →